Brand vs Compounded GLP-1 Medications: What You Need to Know
The date matters here. FDA determined that tirzepatide injection shortage was resolved on December 19, 2024 and semaglutide injection shortage was resolved on February 21, 2025. 21 That means the brand-vs-compounded question in 2026 is different from what it was during the shortage peak. A year ago, many patients were asking, “Can I get anything at all?” Now the harder question is, “When does compounding still make sense, and when is it just a riskier copy?”
This guide is the cheat sheet. It covers what brand GLP-1s offer, what compounded products are and are not, what changed legally after the shortages ended, where the real safety concerns are, and how to screen a pharmacy before money changes hands. For the broader mechanism and drug class overview, start with our complete GLP-1 guide. If you want drug-specific context, read our semaglutide guide and tirzepatide vs. semaglutide comparison.
The Simple Version
Brand GLP-1 medications such as Ozempic, Wegovy, Mounjaro, and Zepbound are FDA-approved drugs. That means FDA reviewed the manufacturing process, labeling, dose strengths, and evidence package before marketing. Compounded GLP-1 products are made by pharmacies or outsourcing facilities for individual prescriptions or facility supply, but they are not FDA-approved. FDA says compounded drugs may be appropriate when a patient’s medical needs cannot be met by an FDA-approved drug or when the approved drug is not commercially available. 4
That difference is the entire story. Brand products come with reviewed evidence, fixed strengths, and standardized instructions. Compounded products may sometimes solve a real access problem, but they come with more uncertainty by design.
What Changed After the Shortages Ended
During the shortage era, compounding expanded because semaglutide and tirzepatide were hard to get. FDA’s later determinations changed that baseline. In its semaglutide decision memorandum dated February 21, 2025, FDA said Novo Nordisk’s supply was meeting or exceeding demand. In its tirzepatide decision memorandum dated December 19, 2024, FDA said Lilly’s supply could meet present and projected national demand. 12
FDA then published specific enforcement-discretion end dates. For routine copies under section 503A, the semaglutide grace period ran until April 22, 2025 and the tirzepatide grace period ran until February 18, 2025. For section 503B outsourcing facilities, the semaglutide grace period ran until May 22, 2025 and the tirzepatide grace period ran until March 19, 2025. 3
The practical implication is straightforward: by March 28, 2026, you should assume that a pharmacy selling a routine compounded copy of semaglutide or tirzepatide needs a stronger patient-specific justification than “the shortage made this common last year.” That is an inference from the FDA shortage-resolution documents and FDA’s enforcement timeline, not a court opinion on any specific seller.
What 503A and 503B Actually Mean
These terms get used like marketing badges, but they mean different things.
Under section 503A, a state-licensed pharmacy or physician compounds for an identified individual patient based on a valid prescription. The law also says 503A compounders should not compound regularly or in inordinate amounts products that are essentially copies of a commercially available drug, unless there is a significant patient-specific difference determined by the prescriber. 6
Under section 503B, a facility can register as an outsourcing facility. FDA says 503B facilities must comply with current good manufacturing practice, are inspected on a risk-based schedule, and must meet additional reporting requirements. 7 But FDA also says registration alone does not mean the facility is FDA-approved or that FDA has determined the facility is currently compliant. 8
That last point matters. “We use a 503B” is better than “trust us,” but it is not the same thing as “this product is FDA-approved.”
What Brand Products Have That Compounded Products Do Not
Brand products are not automatically cheap or easy to get, but they do come with a cleaner evidence trail.
Semaglutide 2.4 mg in the STEP 1 trial produced a mean body-weight reduction of 14.9% at 68 weeks versus 2.4% with placebo. 10 Tirzepatide in SURMOUNT-1 produced mean body-weight reductions of 15.0%, 19.5%, and 20.9% depending on dose, versus 3.1% with placebo. 11
Those trial numbers belong to the studied, labeled products. A compounded product may contain semaglutide or tirzepatide, but it is not automatically interchangeable with the exact product, concentration, device, storage history, and labeling studied in those trials. That does not prove every compounded product is unsafe. It does mean you should not assume the trial results transfer cleanly.
The Safety Concerns Are More Specific Than “Compounded Is Bad”
The strongest argument for caution is not abstract regulation. It is the list of concrete failure modes FDA has already described.
First, compounded GLP-1s do not go through FDA premarket review for safety, effectiveness, or quality. 4
Second, FDA said some compounded injectable GLP-1 products arrived warm or with inadequate ice packs, which can create quality concerns for refrigerated injectables. 4
Third, FDA documented dosing mistakes with compounded semaglutide drawn from multi-dose vials. In reported cases, some patients administered five to 20 times the intended dose and some required medical attention or hospitalization. 5
Fourth, FDA said it had received reports that some compounders were using semaglutide sodium or semaglutide acetate, which are salt forms and not the same active ingredient used in the approved products. FDA said it was not aware of a basis for using those salt forms that would satisfy the compounding conditions in the FD&C Act. 5
Fifth, FDA said some compounders add ingredients such as vitamin B12, vitamin B6, L-carnitine, or NAD to semaglutide products, and that the safety and effectiveness of those combinations has not been established. 5
That is the honest framing: the risks are not just “maybe weaker.” They include concentration confusion, syringe confusion, storage problems, and ingredient differences.
Cost and Access: The Tradeoff Patients Actually Feel
This is why compounded GLP-1s keep getting attention. They can be cheaper up front and sometimes easier to order. Brand products, even with manufacturer programs, still involve real friction.
As of March 28, 2026, Novo Nordisk’s Wegovy site said cash-pay patients could expect to pay $499 per month in one coverage path, while separate self-pay promotional offers listed $199 per month for early low-dose fills through a limited-time program. 12 Lilly’s Zepbound site listed regular self-pay pricing of $299 per month for 2.5 mg, $399 for 5 mg, and $449 for higher doses through its self-pay program, with terms attached. 13
That still leaves many people with a painful spreadsheet. The issue is that a lower sticker price on a compounded product buys less certainty. Here is the fast comparison:
| Question | Brand GLP-1 | Compounded GLP-1 |
|---|---|---|
| FDA approval | Yes | No |
| Standardized pen or vial labeling | Yes | Not necessarily |
| Trial evidence tied to exact product | Yes | No |
| Manufacturer savings programs | Sometimes | Usually no equivalent manufacturer program |
| Can solve a patient-specific need | Sometimes not | Sometimes yes |
| Risk of concentration or syringe confusion | Lower | Higher, especially with multi-dose vials |
If you want the shortest honest answer: brand drugs usually win on evidence and quality control; compounded drugs usually win on flexibility and sometimes price.
How To Evaluate a Compounding Pharmacy
This is the part worth screenshotting.
Ask these seven questions before you pay
- Why is compounding medically necessary for me specifically? If the answer is vague, the case is weak.
- Is the pharmacy state-licensed, and can it verify that license? FDA says patients should fill prescriptions at a state-licensed pharmacy. 4
- If this comes from an outsourcing facility, is that facility currently on FDA’s registered 503B list? Registration is not approval, but absence from the list is still a bad sign. 9
- What exact active ingredient is being used? If the answer includes semaglutide sodium or semaglutide acetate, that is a red flag based on FDA’s warning. 5
- Is anything else mixed in, such as B12 or NAD? If yes, ask what evidence supports the combination.
- How is the product shipped and kept cold? FDA has specifically warned about warm shipments. 4
- What device and concentration am I actually using? A multi-dose vial plus insulin syringe setup raises the chance of a dosing mistake.
Red flags that should make you stop
- The seller says the product is “the same as” Wegovy, Ozempic, Mounjaro, or Zepbound.
- The site offers a prescription with little or no clinical evaluation.
- The product arrives warm, unlabeled, or with confusing dosing instructions.
- The company cannot clearly explain concentration, syringe units, or storage.
If you are buying online, FDA’s BeSafeRx materials are still the right filter: prescription required, real pharmacist access, and no miracle-marketing shortcuts. 4
When Compounding May Still Be Reasonable
The evidence-based answer is narrower than many ads suggest.
Compounding may make more sense when a patient has a documented need that the approved product cannot meet, such as a specific formulation issue or another prescriber-documented reason that creates a significant difference for that patient under 503A. 6 It may also come up when real local supply disruptions still prevent access even though FDA has declared the national shortage resolved. That does happen in practice. FDA itself noted that localized supply disruptions can still occur as products move through the distribution chain. 3
But “may be reasonable” is not the same as “equivalent.” If you are choosing compounded primarily for convenience, be honest that you are trading certainty for access.
Bottom Line
If your question is, “Which option has the cleaner evidence and quality-control story?” the answer is the FDA-approved brand product.
If your question is, “Can a compounded GLP-1 ever be appropriate?” the answer is also yes, but only in a narrower lane than the market often implies, especially after the shortage resolutions of December 19, 2024 for tirzepatide and February 21, 2025 for semaglutide. 21
The practical move is to ask your prescriber one blunt question: what specific problem does the compounded version solve for me that an FDA-approved product does not solve right now? If the answer is clear and documented, that is a real conversation. If the answer is mostly marketing, keep walking.
If you want more evidence-based GLP-1 guides like this, join the newsletter for practical explainers, trial-data cheat sheets, and plain-English access updates.
Last reviewed: March 28, 2026
